Stromal cells downregulate miR-23a-5p to activate protective autophagy in acute myeloid leukemia.
Animals
Apoptosis
/ drug effects
Autophagy
/ drug effects
Bone Marrow Cells
/ drug effects
Daunorubicin
/ pharmacology
Female
Gene Expression Regulation, Neoplastic
/ drug effects
Humans
Leukemia, Myeloid, Acute
/ drug therapy
Male
Mice
MicroRNAs
/ genetics
Neoplasm, Residual
/ genetics
Stromal Cells
/ drug effects
Toll-Like Receptor 2
/ drug effects
Tumor Microenvironment
/ drug effects
Xenograft Model Antitumor Assays
Journal
Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092
Informations de publication
Date de publication:
30 09 2019
30 09 2019
Historique:
received:
03
04
2019
accepted:
05
09
2019
revised:
08
08
2019
entrez:
2
10
2019
pubmed:
2
10
2019
medline:
22
8
2020
Statut:
epublish
Résumé
Complex molecular cross talk between stromal cells and the leukemic cells in bone marrow is known to contribute significantly towards drug-resistance. Here, we have identified the molecular events that lead to stromal cells mediated therapy-resistance in acute myeloid leukemia (AML). Our work demonstrates that stromal cells downregulate miR-23a-5p levels in leukemic cells to protect them from the chemotherapy induced apoptosis. Downregulation of miR-23a-5p in leukemic cells leads to upregulation of protective autophagy by targeting TLR2 expression. Further, autophagy inhibitors when used as adjuvants along with conventional drugs can improve drug sensitivity in vitro as well in vivo in a mouse model of leukemia. Our work also demonstrates that this mechanism of bone marrow stromal cell mediated regulation of miR-23a-5p levels and subsequent molecular events are relevant predominantly in myeloid leukemia. Our results illustrate the critical and dynamic role of the bone marrow microenvironment in modulating miRNA expression in leukemic cells which could contribute significantly to drug resistance and subsequent relapse, possibly through persistence of minimal residual disease in this environment.
Identifiants
pubmed: 31570693
doi: 10.1038/s41419-019-1964-8
pii: 10.1038/s41419-019-1964-8
pmc: PMC6769009
doi:
Substances chimiques
MIRN23a microRNA, human
0
MicroRNAs
0
TLR2 protein, human
0
Toll-Like Receptor 2
0
Daunorubicin
ZS7284E0ZP
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
736Subventions
Organisme : DBT-Wellcome Trust India Alliance
ID : IA/S/15/1/501842
Pays : India
Organisme : Wellcome Trust
Pays : United Kingdom
Références
Trends Mol Med. 2007 Nov;13(11):460-9
pubmed: 18029230
Methods Enzymol. 2009;452:181-97
pubmed: 19200883
Blood. 2016 Sep 1;128(9):1260-9
pubmed: 27268264
Trends Cell Biol. 2014 Mar;24(3):153-60
pubmed: 24125906
Protein Cell. 2017 Apr;8(4):296-301
pubmed: 28028657
Blood. 2017 Mar 23;129(12):1617-1626
pubmed: 28159735
J Clin Oncol. 2010 Aug 20;28(24):3866-71
pubmed: 20644086
Genome Biol. 2010;11(10):R106
pubmed: 20979621
Trends Cell Biol. 2018 Feb;28(2):157-170
pubmed: 29132729
Semin Cancer Biol. 2016 Aug;39:15-25
pubmed: 27402288
Cell Death Dis. 2013 Oct 10;4:e838
pubmed: 24113172
J Mol Diagn. 2015 Nov;17(6):669-78
pubmed: 26433312
Mol Cancer Res. 2016 Oct;14(10):909-919
pubmed: 27358112
Elife. 2015 Aug 12;4:
pubmed: 26267216
Int J Biochem Cell Biol. 2009 Nov;41(11):2225-31
pubmed: 19398036
Int J Biochem Cell Biol. 2012 Sep;44(9):1448-56
pubmed: 22634383
Cell Cycle. 2013 Oct 15;12(20):3262-71
pubmed: 24036551
Nucleic Acids Res. 2014 Jan;42(Database issue):D68-73
pubmed: 24275495
Genome Biol. 2009;10(3):R25
pubmed: 19261174
Biomed Res Int. 2018 Nov 29;2018:1942867
pubmed: 30627542
Autophagy. 2015;11(1):28-45
pubmed: 25484070
Biochim Biophys Acta. 2016 Mar;1863(3):414-426
pubmed: 26255027
Tumour Biol. 2017 Apr;39(4):1010428317695964
pubmed: 28381182
Mol Med Rep. 2018 Jul;18(1):105-112
pubmed: 29749476
Am J Cancer Res. 2012;2(1):65-74
pubmed: 22206046
PLoS One. 2009 Jun 09;4(6):e5848
pubmed: 19513126
Int J Clin Exp Pathol. 2018 Mar 01;11(3):1529-1537
pubmed: 31938250
Exp Cell Res. 2017 May 15;354(2):71-77
pubmed: 28327409
Commun Biol. 2019 May 9;2:176
pubmed: 31098409
Cell Physiol Biochem. 2018;45(4):1581-1589
pubmed: 29482191
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2551-6
pubmed: 9122233
PLoS One. 2015 Mar 30;10(3):e0121912
pubmed: 25822503
Leuk Res. 2015 Mar;39(3):318-22
pubmed: 25624047
Blood. 2012 Nov 8;120(19):3958-67
pubmed: 22983447
J Cell Mol Med. 2017 Dec;21(12):3347-3359
pubmed: 28609022
Nat Rev Cancer. 2009 Sep;9(9):665-74
pubmed: 19693095
Blood. 2016 Sep 22;128(12):1614-24
pubmed: 27480114
Biomark Res. 2014 May 30;2:10
pubmed: 24910775
Blood. 2014 Apr 24;123(17):2691-702
pubmed: 24599548
Cell Mol Life Sci. 2017 May;74(9):1567-1576
pubmed: 27826642
Cell Cycle. 2008 Aug 15;7(16):2493-9
pubmed: 18719378
Oncotarget. 2015 Oct 20;6(32):33554-67
pubmed: 26378023
Leukemia. 2016 Nov;30(11):2169-2178
pubmed: 27560113
Cell. 2014 Oct 23;159(3):499-513
pubmed: 25417103
Mol Ther Nucleic Acids. 2018 Sep 7;12:319-336
pubmed: 30195770
Mol Ther Nucleic Acids. 2016 Oct 11;5(10):e374
pubmed: 27727247
Mol Med Rep. 2017 Aug;16(2):2309-2317
pubmed: 28656260